Figure 1.
Mass fraction evolution across the membrane layer for different values of fKn for Kn = 0.1.
Citation: Vittorio Emanuele Bianchi, Giancarlo Falcioni. Reactive oxygen species, health and longevity[J]. AIMS Molecular Science, 2016, 3(4): 479-504. doi: 10.3934/molsci.2016.4.479
| [1] | Tianyuan Xu, Shanming Ji, Chunhua Jin, Ming Mei, Jingxue Yin . EARLY AND LATE STAGE PROFILES FOR A CHEMOTAXIS MODEL WITH DENSITY-DEPENDENT JUMP PROBABILITY. Mathematical Biosciences and Engineering, 2018, 15(6): 1345-1385. doi: 10.3934/mbe.2018062 |
| [2] | Wenjie Zhang, Lu Xu, Qiao Xin . Global boundedness of a higher-dimensional chemotaxis system on alopecia areata. Mathematical Biosciences and Engineering, 2023, 20(5): 7922-7942. doi: 10.3934/mbe.2023343 |
| [3] | Sunwoo Hwang, Seongwon Lee, Hyung Ju Hwang . Neural network approach to data-driven estimation of chemotactic sensitivity in the Keller-Segel model. Mathematical Biosciences and Engineering, 2021, 18(6): 8524-8534. doi: 10.3934/mbe.2021421 |
| [4] | Qianhong Zhang, Fubiao Lin, Xiaoying Zhong . On discrete time Beverton-Holt population model with fuzzy environment. Mathematical Biosciences and Engineering, 2019, 16(3): 1471-1488. doi: 10.3934/mbe.2019071 |
| [5] | Chichia Chiu, Jui-Ling Yu . An optimal adaptive time-stepping scheme for solving reaction-diffusion-chemotaxis systems. Mathematical Biosciences and Engineering, 2007, 4(2): 187-203. doi: 10.3934/mbe.2007.4.187 |
| [6] | Xu Song, Jingyu Li . Asymptotic stability of spiky steady states for a singular chemotaxis model with signal-suppressed motility. Mathematical Biosciences and Engineering, 2022, 19(12): 13988-14028. doi: 10.3934/mbe.2022652 |
| [7] | Tingting Yu, Sanling Yuan . Dynamics of a stochastic turbidostat model with sampled and delayed measurements. Mathematical Biosciences and Engineering, 2023, 20(4): 6215-6236. doi: 10.3934/mbe.2023268 |
| [8] | Lin Zhang, Yongbin Ge, Zhi Wang . Positivity-preserving high-order compact difference method for the Keller-Segel chemotaxis model. Mathematical Biosciences and Engineering, 2022, 19(7): 6764-6794. doi: 10.3934/mbe.2022319 |
| [9] | Changwook Yoon, Sewoong Kim, Hyung Ju Hwang . Global well-posedness and pattern formations of the immune system induced by chemotaxis. Mathematical Biosciences and Engineering, 2020, 17(4): 3426-3449. doi: 10.3934/mbe.2020194 |
| [10] | Marcin Choiński, Mariusz Bodzioch, Urszula Foryś . A non-standard discretized SIS model of epidemics. Mathematical Biosciences and Engineering, 2022, 19(1): 115-133. doi: 10.3934/mbe.2022006 |
Nanomedicine knows an increasing interest due to its estimated importance in efficient medication delivery [1]. Crucial medical topics deal with its application in several fields, such as overcoming the blood-brain barrier [2], anti-diabetic medication [3] and uptake in endothelial cells [4]. Nanomedicine deals with the novel chemical, physical or biological properties of medication at nanometric scale, as well as the application of nanotechnology aiming at making a medical diagnosis, treating or preventing the cause of illness. Therefore, nanomedicines have the ability, due to their particular size or surface functionality, to demonstrate physicochemical and/or biological properties that make them interesting for medication delivery, controlled medication release and/or improved medication transport through biological barriers, such as cell membranes, which would otherwise be much more difficult [5]. One of the key parameters for successful medication delivery is controlling or improving the permeation of medication through the destined place (e.g. vascular system, cell) in the human body [6,7,8]. When speaking about cell permeation and the body uptake efficiency of drugs into the body that it entails, many works take the apparent cell permeability, Papp, through monolayers of human epithelial cells as a widely accepted standard [9,10,11]. Values of Papp (often presented in medicine as a volumetric flux per unity of area) of such cells are also often used for the estimation of the blood-brain barrier [12,13]. It is useful to understand the apparent cell permeation as a series of parallel and serial resistances (from layer to another). This vision is based on the concept of solubility diffusion [14]. The permeability is seen here, therefore, not as an imposed force, but is rather passive in a way that only spontaneous diffusion governs the permeation process. This diffusion process is determined by a concentration gradient. The concentration gradient is classically described by Fick's law or, in case of sizes (within the membranes separating the monolayers) at nanoscale, by a more general evolution equation, describing the extended diffusion law, as will be discussed later. Active transport, as could be caused by transporter proteins, is not considered here. Although, in reality, chemicals/drugs could be transported by proteins (and thus have an effect on Papp), it is not taken into account here. It is well admitted that generally three pathways are possible through a cellular monolayer, i.e. in between the cells (the paracellular way), through the cell (considered here) and along the membrane solely (the lateral way) [15,16]. In this case, parallel resistances of the three pathways would apply. Here, we only consider the pathway through the cell. Following the pH partition hypothesis [17], it can be assumed that only the neutral form of the drug chemicals can pass the membrane resistances. Therefore, chemicals that are ionized should undergo an acid-base reaction in between the water layer and the membrane before they are able to pass the membrane as a neutral species. According to the aforementioned pH partition hypothesis, such a reaction can be considered to occur instantaneously, meaning that no kinetic hinderness (and therefore no additional resistance) needs to be considered.
It is often suggested that the diffusion through membranes are of non-Fickian nature. We propose that this is either because of non-local effects (the size of the membranes are of the same order of magnitude as the drug molecules or not much bigger) or because the relaxation time becomes important. As controlling and enhancing drug delivery is an important issue in the field of nanomedicine, next to in vitro experiments, modelling is crucial to understand the underlying mechanisms. In nanomedicine, the inertia of the diffusing particles is relevant in addition to the small size of the channels through which the medication passes, being in some cases of the same order of magnitude as the mean free path of the particles. Furthermore, purely microscopic models are often difficult to implement directly to real-life applications. Therefore, further progress in this field can be enhanced by models that are easily applicable, whilst keeping a qualitative efficient and understandable way to link to experiments in a multi-disciplinary way. Therefore, we propose here a model based on thermodynamic principles, where we extend them by incorporating effects, in a rigourous way, that account for the relaxation and size of the drug molecules with respect to the channels through which they diffuse. With the purpose to demonstrate the applicability of our new theory, we treat two cases: drug diffusion through a cell membrane and drug release out of a scaffold. For the first case, let us imagine the existence of two compartments of well-mixed water that are separated by a barrier, i.e. a membrane: the first containing the drug molecules as the donor and the second represents the inner cell or the receptor. The purpose is to follow the evolution of the mass fraction profile through the membrane at the beginning of the diffusion process, where we assume that the drug molecules (in that beginning process) concentration is that high that the mass fraction at the inlet of the membrane is constant. For the second case, we discuss drug release out of a scaffold and follow the concentration profile to assess the rapidity of the drug release. To account for the importance of the relaxation time of the drug molecules and the non-local effects, we propose the formulation of mass transport using Extended Non-Equilibrium Thermodynamics [18,19], whose main characteristic is to upgrade the flux and higher order fluxes to the rank of independent variables.
At micro and nanoscales, mass transport is mostly influenced by non-local effects and relaxation times. The classical Fick law
| J=−ρD∇c, | (1) |
relating the mass flux vector J to the mass fraction gradient ∇c, with ρ and D denoting the density and mass diffusion coefficient, respectively, is not applicable at short diffusional time (with respect to the relaxation time, i.e. large relaxation times) and small spatial scales. In order to account for large relaxation times, Fick's law can be generalized by a Cattaneo-like equation (in analogy to the one used for heat transport [20]) under the form
| τr∂tJ+J=−ρD∇c | (2) |
where τr designates the relaxation time of the mass flux and ∂t the partial time derivative. To account furthermore for non-local effects, Extended Non-Equilibrium Thermodynamics (see for underlying developments in previous work [18]) proposes a further generalization
| τr∂tJ+J=−ρD∇c+ℓ2∇2J | (3) |
It is convenient to reformulate (3) in dimensionless form. Therefore, the mass flux J is rescaled with ρDδ, the space coordinate with a characteristic length δ (standing also for the membrane thickness), the time t with the characteristic diffusion time τd=δ2D. Introducing the Knudsen number Kn≡ℓδ, a dimensional number M=τrτd and using the same notation for the non-dimensional quantities, Eq (3) becomes
| M∂tJ+J=−∇c+Kn2∇2J | (4) |
It should be noted here that by choosing τd as time scale, one implies that any change in M means a change in the relaxation time, which evokes non-local effects. This motivates proposing an adaptation for the expression for M. Indeed, kinetically speaking, one may define a relation D≡13ℓ2τr, in analogy to the thermal conductivity [1]. Using the definition of τd and Kn, one finds a relation M=13Kn2. However, in suspensions, these kinetic considerations are not always valid and differences could occur. Acknowledging that some partial proportionality is admitted between M and the Kn number (the relaxation time and the mean free path are related in that they both can cause non-local effects), this motivates to define rather M=fKn13Kn2. Note that using this definition does not change anything for the analysis to be performed (indeed, in principle, any number could be chosen for M in the framework of a dimensionless analysis conditioned by correct interpretation of the results). Moreover, fKn is a factor that accounts for the observation that in nanofluids the relaxation time is not necessarily fully proportional to the Kn number. This factor also allows investigating separately the effects of the relaxation time and the mean free path on drug diffusion.
We can see clearly differences between (3) and the conventional constitutional Fick's law for mass diffusion (1), but also some similarities. When we deal with systems where the characteristic size is found to be much larger than the mean free path of the molecules l, Eq (3) reduces to the Cattaneo-like equation (2). This would also correspond to neglect any higher order of mass fluxes. Now, when the changes in the mass flux occur in a time span that is much larger than the relaxation time, we obtain Fick's law. Let us stress that the latter issue depends on the physicochemical relation the medication molecule can have with the carrier fluid or the host environment. Other well-known methods that are used for solving models that deal with nanoscale systems are the phonon-Boltzmann equation, Monte Carlo simulations and Molecular Dynamics. The Monte Carlo simulations and Molecular Dynamics method are numerical methods that generally do not require higher order variables, but instead demand high computing times, whilst being less flexible for modelling various scales at a time, although some efforts have been performed concerning multi-scale molecular dynamics [21]. Nonetheless, the flexibility in scale remains less than the present approach. The phonon-Boltzmann equation also demands high computational time for solving a model. The aforementioned aspects are generally less of a problem when it comes to the model that is proposed in this work. It should be noted that the present development could be extended by introducing non-linear mass fluxes or higher-order (higher than the second order) fluxes. However, implementing such an extension, albeit theoretically not an impossible task (see [18]), would introduce numerical difficulties and higher computing time, which is an absent aspect of the present approach. Furthermore, it would also loose the ability to propose analytical solutions for some particular cases, offering a pedagogical presentation allowing easier interpretations. Non-linear contributions of the mass flux (at first and higher orders) could be interesting to consider when the length scale becomes much smaller than the mean free path of the molecules. For the purposes of nanomedicine applications, this would in many cases lead to unnecessary complications. Indeed, for many cases a linear mass flux limited to second-order mass fluxes (which leads to the term ∇2J in (3)) is sufficient. In comparison, it already appeared to be sufficient for heat transport applications [22] and for predicting nanoflow properties [23].
From typical clinical observations that lead to data in the literature, it appears that one of the most important issues to be studied for improving drug delivery are through enhancing the permeability. In porous media, the concentration gradient can be negligible with respect to the flux, which is often the case for nanoporous flow that is pressure-driven by some external pressure. There are some cases in the human body that are comparable from a conceptual point of view, such as oxygen and carbon dioxide transfer from the lungs to the veins within the alveoles. Nonetheless, porous flow within cell membrane pores presents often the difference that, due to the absence of externally imposed pressure, the concentration gradient can be quite important with respect to the flux. In case of passive permeability, one speaks often of diffusional processes. As the diffusion process through the membrane is often the limiting pathway, the flux across the membrane will undergo non-local effects. Flux variation in the perpendicular direction to the flux across the membrane can be neglected, assuming a well-dispersed medication solution at the entrance of the whole membrane. One would then use (3) to describe such a process, reduced to a one-dimensional equation, replacing the ∇ operator by the derivative ∂y. However, the concentration gradient is not simply a gradient of the concentrations from both sides of the membrane, since concentration jumps can exist at the entry or exit of those membranes due to lipid bilayer interaction or wettability effects. The gradient that counts is the one within the membrane. Therefore, it is important to consider the fact that flux by diffusion across a membrane (even if it were uniform) depends on the solubility. As there are different solubilities at both sides of the membrane and within the membrane as well, we can define partition coefficients ϑin and ϑout for the entry and exit of the membrane, respectively:
| ϑin=Nmb,inNin | (5) |
| ϑout=Nmb,outNout | (6) |
where Nmb, in and Nmb, out are the concentrations within the membrane from the entry and exit sides, respectively. Also, Nin and Nout stand for the same concentrations, but at the medium sides (outside the membrane), respectively. It is more convenient to write (5) and (6) in mass fractions, c, where the subscripts mean the same thing as for the concentrations. Assuming ϑin = ϑout≡ϑ, we have
| ϑ=cmb,in(1−cin)cin(1−cmb,in) | (7) |
| ϑ=cmb,out(1−cout)cout(1−cmb,out) | (8) |
where ϑ is to be determined experimentally as a material property. We can readily see that for a higher partition coefficient, the concentration gradient within the membrane is then larger than on the outer sides of the membrane, which results into a higher membrane solubility and thus a higher permeation. To model the whole process, next to the one-dimensional version of Eq (3), the mass fraction evolution is given by the classical species balance equation, which in dimensionless form gives
| ∂tc=−∇⋅J | (9) |
Since the thickness of a cell membrane is much smaller than its size in the other directions, we consider a one-dimensional model through the membrane with thickness δ, assuming that in all directions other than across the membrane the variables remain constant. The entrance of the membrane (at the drug donor side) is denoted by the dimensionless coordinate y = 0 and the exit (at the drug receptor side) by y = 1. The transport of the drug molecules through a cell membrane will then be modeled by the one-dimensional versions of Eqs. (4) and (9)
| M∂tJ+J=−∂yc+Kn2∂2yJ | (10) |
| ∂tc=−∂yJ | (11) |
Here, we omitted the subscript mb for the membrane and will do so in the following. The drug at the donor side of, but outside, the membrane is given by cin. The inner-side drug mass fraction of the membrane at y = 0 is then, via the partition theory, given by
| c|y=0=ϑcin1+(ϑ−−1)cin | (12) |
At the cell-side of the membrane, y = 1, we assume a continuity of fluxes so that
| −D∂c∂y=−Dce∂cce∂y | (13) |
where the subscript ce denotes the inner cell. Assuming that the inner cell is an unstirred well-mixed environment, the drug uptake can be considered to occur under a constant rising concentration. Therefore, the gradient is nearly zero, so that we can say that ∂cce∂y≈0. This allows to state approximately that at y = 1
| ∂c∂y|y=1=0 | (14) |
The initial mass fraction within the membrane is given by
| c|t=0=c0 | (15) |
A supplementary interest is the continuous delivery of drugs out of a scaffold. In this case, a scaffold, containing the drugs, is introduced into the area of interest (the manner in which this is done is not the point of discussion here). This scaffold is a porous structure, where we are interested to provide a tool for analysing the diffusional flow through this medium. One side of the scaffold contains the drugs, maintained at a certain concentration or mass fraction, cin. The other side is where the drugs enter the area of interest, where we assume that the uptake is immediate so that the mass fraction is zero there, i.e. c0 = 0. Let us approximate such a scaffold as cylindrical pores. Contrary to the previous subsection, the dimension of the flux direction (axial direction of the pores) is larger than the radius of such a cylinder (radial direction of the pores). In that case, we can say (and also motivated by previous work in porous systems [23]) that the flux in the axial direction of the pores (the direction of drug release) will be approximately constant. However, the flux will be variable over the radial direction of the flux. Indeed, due to the small pore size with respect to the axial dimension of the pores, the wall effects will influence the flux and a flux profile exists in the radial direction. As for the mass fraction gradient (being a slow variable), its radial gradient is negligible with respect to the axial one (influenced by the drug release). As such, Eq (4) gives in dimensionless form (using ρDR, R and L as scaling for the mass flux, the radial spatial coordinate and the axial spatial coordinate, respectively, where R is the pore radius and L the length of the pore)
| J=−α∂c∂x+Kn2r1r∂∂r(r∂J∂r), | (16) |
with Knr≡ℓR, r the radial spatial coordinate, x the axial spatial coordinate in the pores and α≡RL. Assuming maximum flux in the middle of the pore (r = 0), i.e. ∂J∂r|r=0=0, and first-order slip (defining Bs≡ℓsR, where ℓs stands for the slip length, related to the wall material) at the wall (r = 1), i.e.
| J=−Bs∂J∂r|r=1, | (17) |
the flux can be found as a function of r. Taking subsequently an average value over a cross-section of the cylinder gives the following mass flux
| J=−α∂c∂x(1−2Kn2rB[1,1Knr]KnrB[0,1Knr]+BsB[1,1Knr]) | (18) |
with B the Bessel-I function. It should be noted that Eq (18) depends on how slip is observed and how the mass flux is defined. Other effects can influence the mass flux, but here it is the purpose to show how physical models can be used in the field of nanomedicine. Such an effective flux (taking into account the material of the scaffold (via the slip factor) and non-local effects via the Knudsen number) is now filled in the dimensionless (time scale is taken as L2D) species balance in the flow direction
| ∂tc=−1α∂xJ | (19) |
The evolution of the mass fraction is then described as
| ∂tc=∂2c∂x2(1−2Kn2B[1,1Kn]KnB[0,1Kn]+BsB[1,1Kn]) | (20) |
The boundary condition on one side of the scaffold is given by
| ∂c∂x|x=0=0 | (21) |
at x = 0, which stands for assuming that the drug only goes on one direction and
| c|x=1=c0e−t | (22) |
at x = 1, which allows for a drug uptake relaxation time of the same order of magnitude as the characteristic diffusion time (which is reasonable, considering that transport in cells is mainly of diffusive character), describing the mass fraction going from c0 to 0 (complete drug uptake). This depends of course of the system in question and the area in the body. Nevertheless, studying the effect of non-locality and slip factor on drug uptake, the choice of a relaxation time is not of importance here and does not influence our analysis. Eq (22) also shows the initial condition by evaluating it at t = 0.
The model is solved using a semi-implicit difference method for the spatial discretization and the forward Euler method for the temporal discretization for each time step t. At the beginning of the simulation, the initial conditions are imposed. At a certain time t, the equations for the mass flux and mass fractions are written in matrix form A*V = B, where A is a matrix of dimension (n-2)×(n-2) (n being the number of nodes in the discretized spatial domain and two nodes being dedicated to the boundary conditions, the bulk equations are thus discretized on (n-2) nodes) containing the coefficients in the equations for the mass fractions and mass fluxes at time t+1, V a vector of dimension (n-2) containing the unknown mass fraction and mass flux values at the spatial nodes at time t+1 and B a vector of dimension (n-2) containing the known mass fraction and mass flulx values at time t. Due to the spatial gradients in the bulk equations, the values at nodes 2 and n-1 depend on the boundary values at nodes 1 and n, respectively. The vector V is calculated as V = A-1B. The boundary condition for at the membrane entrance is imposed and held at that value at each time step. The boundary condition at the exit of the membrane at time t+1 is then obtained through the bulk values at time t+1. This procedure is repeated until the relative errors of the bulk and boundary values of both the mass fraction and mass flux between the previous and present loop become smaller than 10-4. The obtained values at time t+1 are stocked in the output matrix and used as the known values for the next time step t+2.
We use our model, given by Eqs. (10)–(12), (14)–(15), and solve it by means of a semi-implicite finite difference algorithm, explained in section 4.1. We take cin = 0.8, c0 = 0 and ϑ = 1 (we neglect the effect of the partition coefficient for the moment). The results are presented in Figures 1-5. Figures 1-3 show the evolution of the mass fraction across the membrane for Kn numbers Kn = 0.1, Kn = 1 and Kn = 10, respectively. The different Kn numbers stand for different sizes of the membrane with respect to the molecular mean free path of the drug molecules in the fluid present in the membrane (which can be taken as a watery solution). Furthermore, for each Kn number different fKn values are used: fKn = 0.1, fKn = 1 and fKn = 10.
We can see that for a given Kn number a higher fKn number (higher relaxation time with respect to a fixed diffusion characteristic time), the evolution of the mass flux is significantly slower, with a large gradient at the membrane entrance. This implies that the mass flux is very high at the membrane entrance but very low at the membrane exit. This effect is precisely referred to as non-locality. It is important here that by choosing the diffusion characteristic time as the scale time, any change in fKn implies a change in the relaxation time. This means that one compares systems with different relaxation times, which illustrates the effect of medication diffusion as a function of different medication-carrier fluid systems. A higher Kn number has the same non-local effect, albeit on the geometrical level (for the same system). This latter effect is not so clearly visible in Figures 1–3, but can be more appreciated looking to the evolution of the mass fraction at the membrane exit y = 1 in Figure 4.
Effectively, Figure 4 shows that a higher Kn number, for all fKn values, results into a lower mass fraction, which is representative for a lower drug diffusion/solubility in the membrane. The non-local effect at high Kn numbers is responsible for a non-Fickian mass fraction profile, which is indicated by a mass fraction at the exit of the membrane that is less than the initial mass fraction at steady state (this in comparison with Fickian behaviour, where for a zero-flux boundary condition, the profile should become flat). This means that for drugs that have large relaxation times or mean free paths, the drug uptake could be troublesome. It is interesting to note that the values shown in Figure 4 are exactly at the membrane exit, but that a mass fraction jump exists just before that exit. Not being well discernible in Figures 1-3, a zoom of some of those curves has been plotted in Figure 5.
This mass fraction jump can be seen clearly in Figure 5 and stems from the non-local behaviour from both the mass flux time derivative (∂tJ) and mass flux diffusion term (∇2J). Now, if the partition coefficient was not at unity, we would have not only a jump due to a non-locality at the membrane side of the interface, but also at the cell side, due the partition coefficient. Figure 6 shows the influence of the partition coefficient on the mass fraction evolution.
It can be seen that a higher partition coefficient results into a higher mass fraction and a higher drug uptake (higher mass fraction at the membrane exit). Since a zero-flux boundary condition (standing for a quick drug diffusion in the cell and not for a wall-like boundary, as is discussed under Eq (13)) is maintained at the membrane exit, the partition coefficient does not affect the mass fraction here. However, it does effect the quantitative value of the mass fraction just outside the membrane (in the cell). The higher the partition coefficient, the lower the mass fraction will be here. Also, as Figure 6 seems to show, a higher partition coefficient does not exhibit a different behaviour of the mass fraction at the membrane exit. That is, a higher partition coefficient gives a higher mass fraction of the drug at the membrane entrance, which translates itself into a higher mass fraction at the membrane exit. Nonetheless, this increase is cancelled by the partition coefficient itself at the membrane exit. This motivates using drugs that have a higher partition coefficient at the membrane entrance, but a lower one at the membrane exit. This would, of course, not lead to a higher total uptake (mass conservation implies that the total quantity of the uptake is equal to the administered quantity), but may lead to a higher efficiency if a higher mass fraction is needed for a better healing in a shorter time period. Having discussed drug uptake by means of drug diffusion through a cell membrane, it is also interesting to provide tools to drug release by scaffolds, applicable in the field of nanomedicine. This is treated in the next subsection.
We use our model, given by Eqs (20)–(22), and solve it in the same way as for the non-local drug diffusion model. We take c0 = 0.8 and present the results in Figures 7 and 8 for different Kn numbers and slip factors Bs. When we take Bs = 0, this stands for a zero slip length of the mass flux. This means that the mass flux at the wall of the pores in the scaffold is equal to zero. However, when Bs→∞, this means that there is full slip at the pore walls and that the mass flux is everywhere equal in the radial direction. We take a value Bs = 10 to be quite large, standing for "large slip" and compare its results to "no-slip". The slip behaviour of the mass flux is not clearly defined in the literature, but is rather often used in the framework of fluid flow, related to its velocity. The very definition of a mass flux in a porous medium being [23]
| J=ϕρf(vf−v) | (23) |
where ϕ is the porosity of the porous medium, ρf the density of the fluid flowing through it, vf the fluid velocity and v the barycentric velocity, we see that the mass flux is directly related to the fluid velocity. If we note that in a two-component system the barycentric velocity is expressed as ρv = ϕρfvf+(1-ϕ)ρsvs, wherein the total mass density ρ is ρ = ϕρf+(1-ϕ)ρs with ρs and vs the density and velocity of the solid component, respectively, and that in case of a scaffold vs = 0, we can quickly see that in (23) the only variable the mass flux is related directly to is the fluid velocity vf. As such, the discussion on the slip factor becomes more physical and understandable.
Figures 7 and 8 show that the Kn number tends to delay the drug release. This suggests that for pores of sizes of the order of magnitude of the mean free path of the drug molecules the drug release is slowed down. On the other hand, in some applications, it is necessary to have pores of such a size. Figure 8 shows that the slower drug release can be compensated by a higher slip factor, which accelerates the release of medication, illustrated by mass fraction profiles that evolve faster with respect to Figure 7. Figure 9 shows the mass fraction evolution for different Kn numbers for "no-slip" (Bs = 0) and "high-slip" (Bs = 10) at the membrane exit (y = 1). It can be seen that indeed, when Bs is increased, the reduction of the mass fraction due to an increase in the Kn number (from Kn = 0.1 to Kn = 1) is compensated, resulting into a similar profile. This confirms that by increasing the slip factor, which amounts to say altering the material properties of the scaffold pores to properties that reduce the interaction with the drug molecule solutions, compensates the reduction of drug release in nanopores.
This work presents new developments in Extended Non-Equilibrium Thermodynamics, proposing a model for studying drug uptake through cell membranes and drug release out of scaffolds. The theory is based on elevating fluxes to the same independent status of the usual variables. In this particular case, the mass flux has the same status as the mass fraction or concentration of the medication solution. This means that the mass flux follows its own evolution next to that of the mass fraction, being connected on an equal level via a species balance. By taking into account the relative importance of the relaxation time with respect to the diffusion characteristic time, and of the mean free path with respect to the system characteristic size, non-local effects are included in this way.
As for the diffusion through a cell membrane, it appeared that for sizes and relaxation times of the order of magnitude of or smaller than the mean free path (Kn = O(1)) and diffusion characteristic time (M = O(1)), respectively, leads to a lower drug uptake. This is due to the non-local effect, mentioned before. Non-Fickian profiles result from this, where it can be seen that at high non-locality a large mass fraction gradient is present close to the membrane entrance, but a nearly horizontal one near the exit. The latter contributes to the reduction of drug uptake. Furthermore, it has also been shown that at the membrane exit, a mass fraction jump (within the membrane) occurs that is not due to the boundary condition, but also due the non-locality effect. This is an effect that has not only been observed for heat transport [25], where it is already an established phenomenon, but also for mass transport [26]. The effect of the partition coefficient on the mass fraction is also studied, since they are typically introduced to account for the typical mass fraction jump (outside the membrane) observed in membrane diffusion studies, though still presenting experimental uncertainty to its precise value [26,27,28]. No particular effect has been observed other than that a higher partition coefficient causes a higher mass fraction jump at the membrane boundaries. If the medication could be chosen in such a way that the partition coefficient is high at the entrance and low at the exit, the efficiency of the medication could be increased if a higher concentration would lead to a better healing. Of course, mass conservation implies that this would not influence the total quantity of the uptake, but rather the speed of uptake, which could influence the kinetics of healing.
As for the drug release from the scaffold, the non-locality effect also showed to have a reducing impact on the release of drugs from the scaffold. It appeared that such a reduction could be countered by choosing the material of the scaffold in such a way that (besides biocompatibility, which is not a complicated task on its own) the interaction between the scaffold pore walls and the medication solution is weakened. This results into a higher slip factor enhancing drug release.
Future developments of this work include experimental demonstration, using the proposed model in this work. As quantitative agreement between experiments and models are difficult to find in the literature, comparison with experimental data should first be performed by nanomaterials of which material properties are well known and documented. As example, we can mention the delivery of nucleic acids with DNA nanostructures as new means of drug delivery by nanocarriers [29,30]. In the case of the nanocarriers, which can also be seen as scaffolds, the diffusion of the carriers through the cell membranes could be described by the set of Eqs (10)–(12) and (14)–(15). Subsequently, the delivery of the drugs out of the carriers into the cells could be described as release from a scaffold by Eqs (20)–(22). The difficulty lies in determining the interaction the medication can have with the nanocarrier, such as the DNA nanostructures [29]. In other words, it is important to know the slip length or slipping coefficient in Eq (17). Enhancement of drug release does not depend only on the release of the drug out of the carrier, but also the solubility of the carrier itself through the cell membranes. It is reported that DNA nanostructures can overcome the usually large circulation times of carriers [29,30]. The aforementioned discussion implies a necessity of measuring some material properties in order to use the presented model in this paper. In some cases, information about material properties could be obtained by in vitro experiments with a controlled experimental setup in a similar way performed by [31] for high-precision regulation of cell behaviour. This brings the intermediate step between modelling and full experimental demonstration to be identified by bio-mimicking cell membranes or scaffolds. Finally, such information can complete an experimental demonstration of our model.
Financial support from BelSPo is acknowledged.
The author declares there is no conflict of interest.
| [1] |
Barja G (2008) The gene cluster hypothesis of aging and longevity. Biogerontology 9: 57-66. doi: 10.1007/s10522-007-9115-5
|
| [2] |
Hayflick L (2007) Biological aging is no longer an unsolved problem. Ann N Y Acad Sci 1100: 1-13. doi: 10.1196/annals.1395.001
|
| [3] |
Kirkwood TB (2005) Understanding the odd science of aging. Cell 120: 437-447. doi: 10.1016/j.cell.2005.01.027
|
| [4] |
Barja G (2004) Aging in vertebrates, and the effect of caloric restriction: a mitochondrial free radical production-DNA damage mechanism? Biol Rev Camb Philos Soc 79: 235-251. doi: 10.1017/S1464793103006213
|
| [5] |
Hutter E, Skovbro M, Lener B, et al. (2007) Oxidative stress and mitochondrial impairment can be separated from lipofuscin accumulation in aged human skeletal muscle. Aging Cell 6: 245-256. doi: 10.1111/j.1474-9726.2007.00282.x
|
| [6] |
Ku HH, Brunk UT, Sohal RS (1993) Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species. Free Radic Biol Med 15: 621-627. doi: 10.1016/0891-5849(93)90165-Q
|
| [7] |
Lambert AJ, Boysen HM, Buckingham JA, et al. (2007) Low rates of hydrogen peroxide production by isolated heart mitochondria associate with long maximum lifespan in vertebrate homeotherms. Aging Cell 6: 607-618. doi: 10.1111/j.1474-9726.2007.00312.x
|
| [8] |
Pamplona R, Portero-Otin M, Requena JR, et al. (1999) A low degree of fatty acid unsaturation leads to lower lipid peroxidation and lipoxidation-derived protein modification in heart mitochondria of the longevous pigeon than in the short-lived rat. Mech Ageing Dev 106: 283-296. doi: 10.1016/S0047-6374(98)00121-3
|
| [9] | Pamplona R, Portero-Otin M, Riba D, et al. (1998) Mitochondrial membrane peroxidizability index is inversely related to maximum life span in mammals. J Lipid Res 39: 1989-1994. |
| [10] | Pamplona R, Barja G, Portero-Otin M (2002) Membrane fatty acid unsaturation, protection against oxidative stress, and maximum life span: a homeoviscous-longevity adaptation? Ann N Y Acad Sci 959: 475-490. |
| [11] | Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78: 547-581. |
| [12] |
Stadtman ER (1992) Protein oxidation and aging. Science 257: 1220-1224. doi: 10.1126/science.1355616
|
| [13] |
Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell 120: 483-495. doi: 10.1016/j.cell.2005.02.001
|
| [14] |
Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95. doi: 10.1152/physrev.00018.2001
|
| [15] |
Lobo V, Patil A, Phatak A, et al. (2010) Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev 4: 118-126. doi: 10.4103/0973-7847.70902
|
| [16] |
Liochev SI (2013) Reactive oxygen species and the free radical theory of aging. Free Radic Biol Med 60: 1-4. doi: 10.1016/j.freeradbiomed.2013.02.011
|
| [17] |
Cencioni C, Spallotta F, Martelli F, et al. (2013) Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci 14: 17643-17663. doi: 10.3390/ijms140917643
|
| [18] |
Brandes RP, Fleming I, Busse R (2005) Endothelial aging. Cardiovasc Res 66: 286-294. doi: 10.1016/j.cardiores.2004.12.027
|
| [19] | Sohal RS, Weindruch R (1996) Oxidative stress, caloric restriction, and aging. Science 273: 59-63. |
| [20] |
Suliman HB, Piantadosi CA (2014) Mitochondrial biogenesis: regulation by endogenous gases during inflammation and organ stress. Curr Pharm Des 20: 5653-5662. doi: 10.2174/1381612820666140306095717
|
| [21] |
Zuo L, He F, Sergakis GG, et al. (2014) Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. Am J Physiol Lung Cell Mol Physiol 307: L205-218. doi: 10.1152/ajplung.00330.2013
|
| [22] |
Nathan C, Cunningham-Bussel A (2013) Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat Rev Immunol 13: 349-361. doi: 10.1038/nri3423
|
| [23] | Kaeberlein M, Rabinovitch PS, Martin GM (2015) Healthy aging: The ultimate preventative medicine. Science 350: 1191-1193. |
| [24] |
Perls T, Terry D (2003) Genetics of exceptional longevity. Exp Gerontol 38: 725-730. doi: 10.1016/S0531-5565(03)00098-6
|
| [25] |
Evert J, Lawler E, Bogan H, et al. (2003) Morbidity profiles of centenarians: survivors, delayers, and escapers. J Gerontol A Biol Sci Med Sci 58: 232-237. doi: 10.1093/gerona/58.3.M232
|
| [26] |
Merriwether DA, Clark AG, Ballinger SW, et al. (1991) The structure of human mitochondrial DNA variation. J Mol Evol 33: 543-555. doi: 10.1007/BF02102807
|
| [27] |
Greaves LC, Taylor RW (2006) Mitochondrial DNA mutations in human disease. IUBMB Life 58: 143- 151. doi: 10.1080/15216540600686888
|
| [28] |
Chinnery PF, Samuels DC, Elson J, et al. (2002) Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism? Lancet 360: 1323-1325. doi: 10.1016/S0140-6736(02)11310-9
|
| [29] |
Tanaka M, Gong J, Zhang J, et al. (2000) Mitochondrial genotype associated with longevity and its inhibitory effect on mutagenesis. Mech Ageing Dev 116: 65-76. doi: 10.1016/S0047-6374(00)00149-4
|
| [30] |
Hulbert AJ, Pamplona R, Buffenstein R, et al. (2007) Life and death: metabolic rate, membrane composition, and life span of animals. Physiol Rev 87: 1175-1213. doi: 10.1152/physrev.00047.2006
|
| [31] |
Munro D, Blier PU (2012) The extreme longevity of Arctica islandica is associated with increased peroxidation resistance in mitochondrial membranes. Aging Cell 11: 845-855. doi: 10.1111/j.1474-9726.2012.00847.x
|
| [32] | Barja G, Herrero A (2000) Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. FASEB J 14: 312-318. |
| [33] | Valls C ,Castelluccio C, Fato R, et al. (1994) Protective effect of exogenous coenzyme q against damage by Adriamycin n perfused rat liver. Biochem Mol Biol Int 33: 633-642. |
| [34] |
Beyer RE, Segura-Aguilar J, Di Bernardo S, et al. (1996) The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci U S A 93: 2528-2532 doi: 10.1073/pnas.93.6.2528
|
| [35] | Trounce I, Byrne E, Marzuki S (1989) Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing. Lancet 1:637-639. |
| [36] |
37. Genova ML, Lenaz G (2015) The Interplay Between Respiratory Supercomplexes and ROS in Aging. Antioxid Redox Signal 23: 208-238. doi: 10.1089/ars.2014.6214
|
| [37] |
38. Ristow M, Schmeisser S (2011) Extending life span by increasing oxidative stress. Free Radic Biol Med 51: 327-336. doi: 10.1016/j.freeradbiomed.2011.05.010
|
| [38] |
39. Wohlgemuth SE, Seo AY, Marzetti E, et al. (2010) Skeletal muscle autophagy and apoptosis during aging: effects of calorie restriction and life-long exercise. Exp Gerontol 45: 1148. doi: 10.1016/j.exger.2009.11.002
|
| [39] | 40. Hood DA (2001) Invited Review: contractile activity-induced mitochondrial biogenesis in skeletal muscle. J Appl Physiol 90: 1137-1157. |
| [40] |
41. Klingenspor M (2003) Cold-induced recruitment of brown adipose tissue thermogenesis. Exp Physiol 88: 141-148. doi: 10.1113/eph8802508
|
| [41] |
42. Civitarese AE, Carling S, Heilbronn LK, et al. (2007) Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 4: e76. doi: 10.1371/journal.pmed.0040076
|
| [42] |
43. Ristow M, Zarse K (2010) How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp Gerontol 45: 410-418. doi: 10.1016/j.exger.2010.03.014
|
| [43] |
44. Ristow M, Schmeisser S (2011) Extending life span by increasing oxidative stress. Free Radic Biol Med 51: 327–336. doi: 10.1016/j.freeradbiomed.2011.05.010
|
| [44] | 45. Sadowska-Bartosz I, Bartosz G (2014) Effect of antioxidants supplementation on aging and longevity. Biomed Res Int 2014: 404680. |
| [45] |
46. Alexander SP, Benson HE, Faccenda E, et al. (2013) The Concise Guide to pharmacology 2013/14: nuclear hormone receptors. Br J Pharmacol 170: 1652-1675. doi: 10.1111/bph.12448
|
| [46] |
47. Goffart S, Wiesner RJ (2003) Regulation and co-ordination of nuclear gene expression during mitochondrial biogenesis. Exp Physiol 88: 33-40. doi: 10.1113/eph8802500
|
| [47] | 48. Scarpulla RC (2008) Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci 11 321-334. |
| [48] |
49. Brenmoehl J, Hoeflich A (2013) Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. Mitochondrion 13: 755-761. doi: 10.1016/j.mito.2013.04.002
|
| [49] |
50. Kong X, Wang R, Xue Y, et al. (2010) Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 5: e11707. doi: 10.1371/journal.pone.0011707
|
| [50] |
51. Yan W, Zhang H, Liu P, et al. (2013) Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1alpha signaling contributing to increased vulnerability in diabetic heart. Basic Res Cardiol 108: 329. doi: 10.1007/s00395-013-0329-1
|
| [51] | 52. Soriano FX, Liesa M, Bach D, et al. (2006) Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. Diabetes 55: 1783-1791. |
| [52] | 53. Bach D, Pich S, Soriano FX, et al. (2003) Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem 278: 17190-17197. |
| [53] |
54. Nisoli E, Valerio A (2014) Healthspan and longevity in mammals: a family game for cellular organelles? Curr Pharm Des 20: 5663-5670. doi: 10.2174/1381612820666140306093651
|
| [54] |
55. Rato L, Duarte AI, Tomas GD, et al. (2014) Pre-diabetes alters testicular PGC1-alpha/SIRT3 axis modulating mitochondrial bioenergetics and oxidative stress. Biochim Biophys Acta 1837: 335-344. doi: 10.1016/j.bbabio.2013.12.008
|
| [55] |
56. Golan R, Scovell JM, Ramasamy R (2015) Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male 18: 201-204. doi: 10.3109/13685538.2015.1052392
|
| [56] |
57. El Khoudary SR, Santoro N, Chen HY, et al. (2016) Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause. Eur J Prev Cardiol 23: 694-703. doi: 10.1177/2047487315607044
|
| [57] | 58. Psarra AM, Sekeris CE (2008) Steroid and thyroid hormone receptors in mitochondria. IUBMB Life 60: 210-223. |
| [58] |
59. Guo W, Wong S, Li M, et al. (2012) Testosterone plus low-intensity physical training in late life improves functional performance, skeletal muscle mitochondrial biogenesis, and mitochondrial quality control in male mice. PLoS One 7:51180. doi: 10.1371/journal.pone.0051180
|
| [59] |
60. Hioki T, Suzuki S, Morimoto M, et al. (2014) Brain testosterone deficiency leads to down-regulation of mitochondrial gene expression in rat hippocampus accompanied by a decline in peroxisome proliferator-activated receptor-gamma coactivator 1alpha expression. J Mol Neurosci 52: 531-537. doi: 10.1007/s12031-013-0108-3
|
| [60] |
61. Capllonch-Amer G, Sbert-Roig M, Galmes-Pascual BM, et al. (2014) Estradiol stimulatesmitochondrial biogenesis and adiponectin expression in skeletal muscle. J Endocrinol 221: 391-403. doi: 10.1530/JOE-14-0008
|
| [61] | 62. Capllonch-Amer G, Llado I, Proenza AM, et al. (2014) Opposite effects of 17-beta estradiol and testosterone on mitochondrial biogenesis and adiponectin synthesis in white adipocytes. J Mol Endocrinol 52: 203-214. |
| [62] |
63. Qiao L, Kinney B, Yoo HS, et al. (2012) Adiponectin increases skeletal muscle mitochondrial biogenesis by suppressing mitogen-activated protein kinase phosphatase-1. Diabetes 61: 1463- 1470. doi: 10.2337/db11-1475
|
| [63] |
64. Casas F, Pessemesse L, Grandemange S, et al. (2009) Overexpression of the mitochondria receptor induces skeletal muscle atrophy during aging. PLoS One 4: e5. doi: 10.1371/journal.pone.0005631
|
| [64] |
65. Skov V, Glintborg D, Knudsen S, et al. (2007) Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes 56: 2349-2355. doi: 10.2337/db07-0275
|
| [65] | 66. Wang M, Wang XC, Zhang ZY, et al. (2010) Impaired mitochondrial oxidative phosphorylation in multiple insulin-sensitive tissues of humans with type 2 diabetes mellitus. J Int Med Res 38: 769- 781. |
| [66] |
67. Boirie Y (2003) Insulin regulation of mitochondrial proteins and oxidative phosphorylation in human muscle. Trends Endocrinol Metab 14: 393-394. doi: 10.1016/j.tem.2003.09.002
|
| [67] | 68. Asmann YW, Stump CS, Short KR, et al. (2006) Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia. Diabetes 55: 3309-3319. |
| [68] | 69. Pei H, Yang Y, Zhao H, et al. (2016) The Role of Mitochondrial Functional Proteins in ROS Production in Ischemic Heart Diseases. Oxid Med Cell Longev 2016: 5470457. |
| [69] |
70. Gilgun-Sherki Y, Melamed E, Offen D (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40: 959-975. doi: 10.1016/S0028-3908(01)00019-3
|
| [70] | 71. Lightowlers RN, Taylor RW, Turnbull DM (2015) Mutations causing mitochondrial disease: What is new and what challenges remain? Science 349: 1494-1499 |
| [71] |
72. Uittenbogaard M, Chiaramello A (2014) Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr Pharm Des 20: 5574-5593. doi: 10.2174/1381612820666140305224906
|
| [72] | 73. Wu SB, Ma YS, Wu YT, et al. (2010) Mitochondrial DNA mutation-elicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome. Mol Neurobiol 41: 256-266. |
| [73] |
74. Powers SK, Jackson MJ (2008) Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev 88: 1243-1276. doi: 10.1152/physrev.00031.2007
|
| [74] |
75. Tsutsui H, Kinugawa S, Matsushima S (2011) Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 301: H2181-2190 doi: 10.1152/ajpheart.00554.2011
|
| [75] |
76. Burgoyne JR, Mongue-Din H, Eaton P, et al. (2012) Redox signaling in cardiac physiology and pathology. Circ Res 111: 1091-1106 doi: 10.1161/CIRCRESAHA.111.255216
|
| [76] |
77. Sag CM, Kohler AC, Anderson ME, et al. (2011) CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol 51: 749- 759. doi: 10.1016/j.yjmcc.2011.07.016
|
| [77] |
78. Kim SJ, Cheresh P, Jablonski RP, et al. (2015) The Role of Mitochondrial DNA in Mediating Alveolar Epithelial Cell Apoptosis and Pulmonary Fibrosis. Int J Mol Sci 16: 21486-21519. doi: 10.3390/ijms160921486
|
| [78] |
79. Rato L, Alves MG, Cavaco JE, et al. (2014) High-energy diets: a threat for male fertility? Obes Rev 15: 996-1007. doi: 10.1111/obr.12226
|
| [79] |
80. Rato L, Alves MG, Dias TR, et al. (2013) High-energy diets may induce a pre-diabetic state altering testicular glycolytic metabolic profile and male reproductive parameters. Andrology 1: 495-504. doi: 10.1111/j.2047-2927.2013.00071.x
|
| [80] |
81. Wu YT, Wu SB, Wei YH (2014) Metabolic reprogramming of human cells in response to oxidative stress: implications in the pathophysiology and therapy of mitochondrial diseases. Curr Pharm Des 20: 5510-5526. doi: 10.2174/1381612820666140306103401
|
| [81] |
82. Wang Y, Oxer D, Hekimi S (2015) Mitochondrial function and lifespan of mice with controlled ubiquinone biosynthesis. Nat Commun 6: 6393. doi: 10.1038/ncomms7393
|
| [82] |
83. Zuo L, Nogueira L, Hogan MC (2011) Reactive oxygen species formation during tetanic contractions in single isolated Xenopus myofibers. J Appl Physiol (1985) 111: 898-904. doi: 10.1152/japplphysiol.00398.2011
|
| [83] | 84. Zuo L, Shiah A, Roberts WJ, et al. (2013) Low Po(2) conditions induce reactive oxygen species formation during contractions in single skeletal muscle fibers. Am J Physiol Regul Integr Comp Physiol 304: R1009-1016. |
| [84] |
85. Zuo L, Best TM, Roberts WJ, et al. (2015) Characterization of reactive oxygen species in diaphragm. Acta Physiol (Oxf) 213: 700-710. doi: 10.1111/apha.12410
|
| [85] |
86. Reid MB, Moylan JS (2011) Beyond atrophy: redox mechanisms of muscle dysfunction in chronic inflammatory disease. J Physiol 589: 2171-2179. doi: 10.1113/jphysiol.2010.203356
|
| [86] |
87. Merry TL, Lynch GS, McConell GK (2010) Downstream mechanisms of nitric oxide-mediated skeletal muscle glucose uptake during contraction. Am J Physiol Regul Integr Comp Physiol 299: R1656- 1665. doi: 10.1152/ajpregu.00433.2010
|
| [87] |
88. Powers SK, Talbert EE, Adhihetty PJ (2011) Reactive oxygen and nitrogen species as intracellular signals in skeletal muscle. J Physiol 589: 2129-2138. doi: 10.1113/jphysiol.2010.201327
|
| [88] |
89. Powers SK, Duarte J, Kavazis AN, et al. (2010) Reactive oxygen species are signalling molecules for skeletal muscle adaptation. Exp Physiol 95: 1-9. doi: 10.1113/expphysiol.2009.050526
|
| [89] |
90. Bassel-Duby R, Olson EN (2006) Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 75: 19-37. doi: 10.1146/annurev.biochem.75.103004.142622
|
| [90] |
91. Vollaard NB, Shearman JP, Cooper CE (2005) Exercise-induced oxidative stress:myths, realities and physiological relevance. Sports Med 35: 1045-1062. doi: 10.2165/00007256-200535120-00004
|
| [91] | 92. Barbieri E, Sestili P (2012) Reactive oxygen species in skeletal muscle signaling. J Signal Transduct 2012: 982794. |
| [92] |
93. Close GL, Ashton T, Cable T, et al. (2004) Eccentric exercise, isokinetic muscle torque and delayed onset muscle soreness: the role of reactive oxygen species. Eur J Appl Physiol 91: 615-621. doi: 10.1007/s00421-003-1012-2
|
| [93] |
94. Kuwahara H, Horie T, Ishikawa S, et al. (2010) Oxidative stress in skeletal muscle causes severe disturbance of exercise activity without muscle atrophy. Free Radic Biol Med 48: 1252-1262. doi: 10.1016/j.freeradbiomed.2010.02.011
|
| [94] | 95. Zuo L, Pannell BK (2015) Redox Characterization of Functioning Skeletal Muscle. Front Physiol 6: 338. |
| [95] |
96. Lustgarten MS, Jang YC, Liu Y, et al. (2011) MnSOD deficiency results in elevated oxidative stress and decreased mitochondrial function but does not lead to muscle atrophy during aging. Aging Cell 10: 493-505. doi: 10.1111/j.1474-9726.2011.00695.x
|
| [96] |
97. Gomez-Cabrera MC, Domenech E, Vina J (2008) Moderate exercise is an antioxidant: upregulation of antioxidant genes by training. Free Radic Biol Med 44: 126-131. doi: 10.1016/j.freeradbiomed.2007.02.001
|
| [97] | 98. Adhihetty PJ, Ljubicic V, Hood DA (2007) Effect of chronic contractile activity on SS and IMF mitochondrial apoptotic susceptibility in skeletal muscle. Am J Physiol Endocrinol Metab 292: E748- 755. |
| [98] | 99. Joseph AM, Adhihetty PJ, Leeuwenburgh C (2015) Beneficial effects of exercise on age-related mitochondrial dysfunction and oxidative stress in skeletal muscle. J Physiol 594: 5105-5123. |
| [99] |
100. Russell AP, Foletta VC, Snow RJ, et al. (2014) Skeletal muscle mitochondria: a major player in exercise, health and disease. Biochim Biophys Acta 1840: 1276-1284. doi: 10.1016/j.bbagen.2013.11.016
|
| [100] | 101. Sachdev S, Davies KJ (2008) Production, detection, and adaptive responses to free radicals in exercise. Free Radic Biol Med 44: 215-223. |
| [101] |
102. Mrakic-Sposta S, Gussoni M, Moretti S, et al. (2015) Effects of Mountain Ultra-Marathon Running on ROS Production and Oxidative Damage by Micro-Invasive Analytic Techniques. PLoS One 10: e0141780. doi: 10.1371/journal.pone.0141780
|
| [102] |
103. Vezzoli A, Pugliese L, Marzorati M, et al. (2014) Time-course changes of oxidative stress response to high-intensity discontinuous training versus moderate-intensity continuous training in masters runners. PLoS One 9: e87506. doi: 10.1371/journal.pone.0087506
|
| [103] |
104. Little JP, Safdar A, Wilkin GP, et al. (2010) A practical model of low-volume high-intensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms. J Physiol 588: 1011-1022. doi: 10.1113/jphysiol.2009.181743
|
| [104] |
105. Hood MS, Little JP, Tarnopolsky MA, et al. (2011) Low-volume interval training improves muscle oxidative capacity in sedentary adults. Med Sci Sports Exerc 43: 1849-1856. doi: 10.1249/MSS.0b013e3182199834
|
| [105] |
106. Powers SK, Smuder AJ, Judge AR (2012) Oxidative stress and disuse muscle atrophy: cause or consequence? Curr Opin Clin Nutr Metab Care 15: 240-245. doi: 10.1097/MCO.0b013e328352b4c2
|
| [106] |
107. Powers SK, Kavazis AN, McClung JM (2007) Oxidative stress and disuse muscle atrophy. J Appl Physiol 102: 2389-2397. doi: 10.1152/japplphysiol.01202.2006
|
| [107] |
108. Owers SK, Hudson MB, Nelson WB, et al. (2011) Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness. Crit Care Med 39: 1749-1759. doi: 10.1097/CCM.0b013e3182190b62
|
| [108] | 109. Powers SK, Kavazis AN, DeRuisseau KC (2005) Mechanisms of disuse muscle atrophy: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol 288: R337-344. |
| [109] |
110. Pellegrino MA, Desaphy JF, Brocca L, et al. (2011) Redox homeostasis, oxidative stress and disuse muscle atrophy. J Physiol 589: 2147-2160. doi: 10.1113/jphysiol.2010.203232
|
| [110] | 111. Ghosh S, Karin M (2002) Missing pieces in the NF-B puzzle. Cell Suppl 109: S81-S96. |
| [111] |
112. Powers SK, Smuder AJ, Criswell DS (2011) Mechanistic links between oxidative stress and disuse muscle atrophy. Antioxid Redox Signal 15: 2519-2528. doi: 10.1089/ars.2011.3973
|
| [112] | 113. Muller FL, Song W, Jang YC, et al. (2007) Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. Am J Physiol Regul Integr Comp Physiol 293: R1159- 1168. |
| [113] | 114. Wong RSY (2011) Apoptosis in cancer: from pathogenesis to treatment. JECCR 30: 87. |
| [114] |
115. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305: 626-629. doi: 10.1126/science.1099320
|
| [115] | 116. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281: 1312-1316. |
| [116] |
117. Braga M, Sinha Hikim AP, Datta S, et al. (2008) Involvement of oxidative stress and caspase 2- mediated intrinsic pathway signaling in age-related increase in muscle cell apoptosis in mice. Apoptosis 13: 822-832. doi: 10.1007/s10495-008-0216-7
|
| [117] |
118. Siu PM, Wang Y, Alway SE (2009) Apoptotic signaling induced by H2O2-mediated oxidative stress in differentiated C2C12 myotubes. Life Sci 84: 468-481. doi: 10.1016/j.lfs.2009.01.014
|
| [118] |
119. Whidden MA, Smuder AJ, Wu M, et al. (2010) Oxidative stress is required for mechanical ventilation-induced protease activation in the diaphragm. J Appl Physiol (1985) 108: 1376-1382. doi: 10.1152/japplphysiol.00098.2010
|
| [119] |
120. Du J, Wang X, Miereles C, et al. (2004) Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113: 115-123. doi: 10.1172/JCI18330
|
| [120] |
121. McClung JM, Kavazis AN, DeRuisseau KC, et al. (2007) Caspase-3 regulation of diaphragm myonuclear domain during mechanical ventilation-induced atrophy. Am J Respir Crit Care Med 175:150-159. doi: 10.1164/rccm.200601-142OC
|
| [121] |
122. Radak Z, Chung HY, Goto S (2005) Exercise and hormesis: oxidative stress-related adaptation for successful aging. Biogerontology 6: 71-75. doi: 10.1007/s10522-004-7386-7
|
| [122] | 123. Bishop NA, Guarente L (2007) Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet 8: 835-844. |
| [123] |
124. Willcox BJ, Willcox DC, Todoriki H, et al. (2007) Caloric restriction, the traditional Okinawan diet, and healthy aging: the diet of the world's longest-lived people and its potential impact on morbidity and life span. Ann N Y Acad Sci 1114: 434-455. doi: 10.1196/annals.1396.037
|
| [124] |
125. Fontana L, Partridge L, Longo VD (2010) Extending healthy life span--from yeast to humans. Science 328: 321-326. doi: 10.1126/science.1172539
|
| [125] |
126. Spindler SR (2010) Caloric restriction: from soup to nuts. Ageing Res Rev 9: 324-353. doi: 10.1016/j.arr.2009.10.003
|
| [126] |
127. Sohal RS, Agarwal S, Candas M, et al. (1994) Effect of age and caloric restriction on DNA oxidative damage in different tissues of C57BL/6 mice. Mech Ageing Dev 76: 215-224. doi: 10.1016/0047-6374(94)91595-4
|
| [127] |
128. Barja G (2002) Endogenous oxidative stress: relationship to aging, longevity and caloric restriction. Ageing Res Rev 1: 397-411. doi: 10.1016/S1568-1637(02)00008-9
|
| [128] |
129. Matsuo M, Gomi F, Kuramoto K, et al. (1993) Food restriction suppresses an age-dependent increase in the exhalation rate of pentane from rats: a longitudinal study. J Gerontol 48: B133-136. doi: 10.1093/geronj/48.4.B133
|
| [129] | 130. Gredilla R, Sanz A, Lopez-Torres M, et al. (2001) Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart. FASEB J 15: 1589-1591. |
| [130] |
131. Masoro EJ (1988) Physiological system markers of aging. Exp Gerontol 23: 391-397. doi: 10.1016/0531-5565(88)90043-5
|
| [131] |
132. Miller RA, Buehner G, Chang Y, et al. (2005) Methionine-deficient diet extends mouse lifespan, slows immune and lens aging, alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte MIF levels and stress resistance. Aging Cell 4: 119-125. doi: 10.1111/j.1474-9726.2005.00152.x
|
| [132] |
133. Speakman JR, Mitchell SE (2011) Caloric restriction. Mol Aspects Med 32: 159-221. doi: 10.1016/j.mam.2011.07.001
|
| [133] |
134. Colman RJ, Anderson RM, Johnson SC, et al. (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325: 201-204. doi: 10.1126/science.1173635
|
| [134] |
135. Barja G (2013) Updating the mitochondrial free radical theory of aging: an integrated view, key aspects, and confounding concepts. Antioxid Redox Signal 19: 1420-1445. doi: 10.1089/ars.2012.5148
|
| [135] | 136. Lambert AJ, Merry BJ (2004) Effect of caloric restriction on mitochondrial reactive oxygen species production and bioenergetics: reversal by insulin. Am J Physiol Regul Integr Comp Physiol 286: R71- 79. |
| [136] |
137. Rebrin I, Kamzalov S, Sohal RS (2003) Effects of age and caloric restriction on glutathione redox state in mice. Free Radic Biol Med 35: 626-635. doi: 10.1016/S0891-5849(03)00388-5
|
| [137] | 138. Dubey A, Forster MJ, Lal H, et al. (1996) Effect of age and caloric intake on protein oxidation in different brain regions and on behavioral functions of the mouse. Arch Biochem Biophys 333: 189- 197. |
| [138] |
139. Lass A, Sohal BH, Weindruch R, et al. (1998) Caloric restriction prevents age-associated accrual of oxidative damage to mouse skeletal muscle mitochondria. Free Radic Biol Med 25: 1089-1097. doi: 10.1016/S0891-5849(98)00144-0
|
| [139] | 140. Heilbronn LK, de Jonge L, Frisard MI, et al. (2006) Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 295: 1539-1548. |
| [140] |
141. Fontana L, Meyer TE, Klein S, et al. (2004) Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A 101: 6659-6663. doi: 10.1073/pnas.0308291101
|
| [141] |
142. Yu BP (1996) Aging and oxidative stress: modulation by dietary restriction. Free Radic Biol Med 21: 651-668. doi: 10.1016/0891-5849(96)00162-1
|
| [142] |
143. Masoro EJ (2009) Caloric restriction-induced life extension of rats and mice: a critique of proposed mechanisms. Biochim Biophys Acta 1790: 1040-1048. doi: 10.1016/j.bbagen.2009.02.011
|
| [143] | 144. Merry BJ (2002) Molecular mechanisms linking calorie restriction and longevity. Int J Biochem Cell Biol 34: 1340-1354. |
| [144] |
145. McDonald RB, Ramsey JJ (2010) Honoring Clive McCay and 75 years of calorie restriction research. J Nutr 140: 1205-1210. doi: 10.3945/jn.110.122804
|
| [145] |
146. Li Y, Daniel M, Tollefsbol TO (2011) Epigenetic regulation of caloric restriction in aging. BMC Med 9: 98. doi: 10.1186/1741-7015-9-98
|
| [146] |
147. Ostergaard JN, Gronbaek M, Schnohr P, et al. (2010) Combined effects of weight loss and physical activity on all-cause mortality of overweight men and women. Int J Obes (Lond) 34: 760-769. doi: 10.1038/ijo.2009.274
|
| [147] |
148. Nanri A, Mizoue T, Takahashi Y, et al. (2010) Weight change and all-cause, cancer and cardiovascular disease mortality in Japanese men and women: the Japan Public Health Center- Based Prospective Study. Int J Obes (Lond) 34: 348-356. doi: 10.1038/ijo.2009.234
|
| [148] | 149. Romero-Corral A, Montori VM, Somers VK, et al. (2006) Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368: 666-678. |
| [149] |
150. De Schutter A, Lavie CJ, Patel DA, et al. (2013) Relation of body fat categories by Gallagher classification and by continuous variables to mortality in patients with coronary heart disease. Am J Cardiol 111: 657-660. doi: 10.1016/j.amjcard.2012.11.013
|
| [150] |
151. Lavie CJ, De Schutter A, Parto P, et al. (2016) Obesity and Prevalence of Cardiovascular Diseases and Prognosis-The Obesity Paradox Updated. Prog Cardiovasc Dis 58: 537-547. doi: 10.1016/j.pcad.2016.01.008
|
| [151] |
152. Dellagrana RA, Guglielmo LG, Santos BV, et al. (2015) Physiological, anthropometric, strength, and muscle power characteristics correlates with running performance in young runners. J Strength Cond Res 29: 1584-1591. doi: 10.1519/JSC.0000000000000784
|
| [152] |
153. Sabino PG, Silva BM, Brunetto AF (2010) Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients. Clinics (Sao Paulo) 65: 599-605. doi: 10.1590/S1807-59322010000600007
|
| [153] |
154. Ruiz JR, Sui X, Lobelo F, et al. (2008) Association between muscular strength and mortality in men: prospective cohort study. BMJ 337: a439. doi: 10.1136/bmj.a439
|
| [154] |
155. Deutz NE, Bauer JM, Barazzoni R, et al. (2014) Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clin Nutr 33: 929-936. doi: 10.1016/j.clnu.2014.04.007
|
| [155] |
156. Izawa KP, Watanabe S, Hirano Y, et al. (2014) The relation between Geriatric Nutritional Risk Index and muscle mass, muscle strength, and exercise capacity in chronic heart failure patients. Int J Cardiol 177: 1140-1141. doi: 10.1016/j.ijcard.2014.08.045
|
| [156] |
157. Victor VM, Rovira-Llopis S, Saiz-Alarcon V, et al. (2014) Altered mitochondrial function and oxidative stress in leukocytes of anorexia nervosa patients. PLoS One 9: e106463. doi: 10.1371/journal.pone.0106463
|
| [157] |
158. Rani V, Deep G, Singh RK, et al. (2016) Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci 148: 183-193. doi: 10.1016/j.lfs.2016.02.002
|
| [158] |
159. Keaney JF, Jr., Larson MG, Vasan RS, et al. (2003) Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23: 434-439. doi: 10.1161/01.ATV.0000058402.34138.11
|
| [159] |
160. Olusi SO (2002) Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int J Obes Relat Metab Disord 26: 11164. doi: 10.1038/sj.ijo.0802066
|
| [160] | 161. Prieto D, Contreras C, Sanchez A (2014) Endothelial dysfunction, obesity and insulin resistance. Curr Vasc Pharmacol 12: 412-426. |
| [161] |
162. Williams IL, Wheatcroft SB, Shah AM, et al. (2002) Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 26: 754-764. doi: 10.1038/sj.ijo.0801995
|
| [162] | 163. Harrison DG (1997) Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-2157. |
| [163] | 164. Hausman GJ, Barb CR (2010) Adipose tissue and the reproductive axis: biological aspects. Endocr Dev 19: 31-44. |
| [164] |
165. Henry BA, Clarke IJ (2008) Adipose tissue hormones and the regulation of food intake. J Neuroendocrinol 20: 842-910. doi: 10.1111/j.1365-2826.2008.1730.x
|
| [165] |
166. Small CJ, Stanley SA, Bloom SR (2002) Appetite control and reproduction: leptin and beyond. Semin Reprod Med 20: 389-398. doi: 10.1055/s-2002-36712
|
| [166] |
167. Rahmouni K (2007) Differential Control of the Sympathetic Nervous System by Leptin: Implications for Obesity. Clin Exp Pharmacol Physiol Suppl 34: S8-S10. doi: 10.1111/j.1440-1681.2007.04760.x
|
| [167] |
168. Korda M, Kubant R, Patton S, et al. (2008) Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 295: H1514-1521. doi: 10.1152/ajpheart.00479.2008
|
| [168] |
169. Blanca AJ, Ruiz-Armenta MV, Zambrano S, et al. (2016) Leptin Induces Oxidative Stress through Activation of NADPH Oxidase in Renal Tubular Cells: Antioxidant Effect of L-Carnitine. J Cell Biochem 117: 2281-2288. doi: 10.1002/jcb.25526
|
| [169] |
170. Lightfoot AP, McCormick R, Nye GA, et al. (2014) Mechanisms of skeletal muscle ageing; avenues for therapeutic intervention. Curr Opin Pharmacol 16: 116-121. doi: 10.1016/j.coph.2014.05.005
|
| [170] |
171. Anderson EJ, Lustig ME, Boyle KE, et al. (2009) Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119: 573-581. doi: 10.1172/JCI37048
|
| [171] |
172. Yang S, Zhu H, Li Y, et al. (2000) Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 378: 259-268. doi: 10.1006/abbi.2000.1829
|
| [172] |
173. Abdul-Ghani MA, Jani R, Chavez A, et al. (2009) Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants. Diabetologia 52: 574-582. doi: 10.1007/s00125-009-1264-4
|
| [173] |
174. Phielix E, Schrauwen-Hinderling VB, Mensink M, et al. (2008) Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes 57: 2943-2949. doi: 10.2337/db08-0391
|
| [174] |
175. Mogensen M, Sahlin K, Fernstrom M, et al. (2007) Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 56: 1592-1599. doi: 10.2337/db06-0981
|
| [175] |
176. Loh K, Deng H, Fukushima A, et al. (2009) Reactive oxygen species enhance insulin sensitivity. Cell Metab 10: 260-272. doi: 10.1016/j.cmet.2009.08.009
|
| [176] |
177. Evans JL, Goldfine ID, Maddux BA, et al. (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599-622. doi: 10.1210/er.2001-0039
|
| [177] | 178. Kim JA, Wei Y, Sowers JR (2008) Role of mitochondrial dysfunction in insulin resistance. Circ Res 102: 401-414. |
| [178] |
179. De Filippis E, Alvarez G, Berria R, et al. (2008) Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. Am J Physiol Endocrinol Metab 294: E607-614. doi: 10.1152/ajpendo.00729.2007
|
| [179] | 180. Dela F, Larsen JJ, Mikines KJ, et al. (1995) Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training. Diabetes 44: 1010-1020. |
| [180] | 181. Bruce CR, Hawley JA (2004) Improvements in insulin resistance with aerobic exercise training: a lipocentric approach. Med Sci Sports Exerc 36: 1196-1201 |
| [181] |
182. Meex RC, Schrauwen-Hinderling VB, Moonen-Kornips E, et al. (2010) Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. Diabetes 59: 572-579. doi: 10.2337/db09-1322
|
| [182] | 183. Phielix E, Meex R, Moonen-Kornips E, et al. (2010) Exercise training increases mitochondrial content and ex vivo mitochondrial function similarly in patients with type 2 diabetes and in control individuals. Diabetologia 53: 1714-1721. |
| [183] |
184. Hey-Mogensen M, Hojlund K, Vind BF, et al. (2010) Effect of physical training on mitochondrial respiration and reactive oxygen species release in skeletal muscle in patients with obesity and type 2 diabetes. Diabetologia 53: 1976-1985. doi: 10.1007/s00125-010-1813-x
|
| [184] |
185. Iwasaki K, Gleiser CA, Masoro EJ, et al. (1988) Influence of the restriction of individual dietary components on longevity and age-related disease of Fischer rats: the fat component and the mineral component. J Gerontol 43: B13-21. doi: 10.1093/geronj/43.1.B13
|
| [185] |
186. Stoltzner G (1977) Effects of life-long dietary protein restriction on mortality, growth, organ weights, blood counts, liver aldolase and kidney catalase in Balb/C mice. Growth 41: 337-348. doi: 10.1016/0022-0248(77)90067-7
|
| [186] |
187. Grandison RC, Piper MD, Partridge L (2009) Amino-acid imbalance explains extension of lifespan by dietary restriction in Drosophila. Nature 462: 1061-1064. doi: 10.1038/nature08619
|
| [187] |
188. Dick KB, Ross CR, Yampolsky LY (2011) Genetic variation of dietary restriction and the effects of nutrient-free water and amino acid supplements on lifespan and fecundity of Drosophila. Genet Res (Camb) 93: 265-273. doi: 10.1017/S001667231100019X
|
| [188] |
189. D'Antona G, Ragni M, Cardile A, et al. (2010) Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. Cell Metab 12: 362-372. doi: 10.1016/j.cmet.2010.08.016
|
| [189] |
190. Zimmerman JA, Malloy V, Krajcik R, et al. (2003) Nutritional control of aging. Exp Gerontol 38: 47- 52. doi: 10.1016/S0531-5565(02)00149-3
|
| [190] |
191. Perrone CE, Mattocks DA, Jarvis-Morar M, et al. (2010) Methionine restriction effects on mitochondrial biogenesis and aerobic capacity in white adipose tissue, liver, and skeletal muscle of F344 rats. Metabolism 59: 1000-1011. doi: 10.1016/j.metabol.2009.10.023
|
| [191] |
192. De AK, Chipalkatti S, Aiyar AS (1983) Some biochemical parameters of ageing in relation to dietary protein. Mech Ageing Dev 21: 37-48. doi: 10.1016/0047-6374(83)90014-3
|
| [192] |
193. Mair W, Piper MD, Partridge L (2005) Calories do not explain extension of life span by dietary restriction in Drosophila. PLoS Biol 3: e223. doi: 10.1371/journal.pbio.0030223
|
| [193] |
194. Minor RK, Smith DL Jr, Sossong AM, et al. (2010) Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol Appl Pharmacol 243: 332-339. doi: 10.1016/j.taap.2009.11.025
|
| [194] |
195. Heinrich LF, Andersen DK, Cleasby ME, et al. (2015) Long-term high-fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells. Br J Nutr 113: 1704-1711. doi: 10.1017/S0007114515001117
|
| [195] |
196. Vial G, Dubouchaud H, Couturier K, et al. (2011) Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol 54: 348-356. doi: 10.1016/j.jhep.2010.06.044
|
| [196] |
197. Moro T, Nakao S, Sumiyoshi H, et al. (2016) A Combination of Mitochondrial Oxidative Stress and Excess Fat/Calorie Intake Accelerates Steatohepatitis by Enhancing Hepatic CC Chemokine Production in Mice. PLoS One 11: e0146592. doi: 10.1371/journal.pone.0146592
|
| [197] |
198. Tresserra-Rimbau A, Medina-Remon A, Perez-Jimenez J, et al. (2013) Dietary intake and major food sources of polyphenols in a Spanish population at high cardiovascular risk: the PREDIMED study. Nutr Metab Cardiovasc Dis 23: 953-959. doi: 10.1016/j.numecd.2012.10.008
|
| [198] |
199. Urpi-Sarda M, Casas R, Chiva-Blanch G, et al. (2012) Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomarkers related to atherosclerosis. Pharmacol Res 65: 577-583. doi: 10.1016/j.phrs.2012.03.006
|
| [199] | 200. Medina-Remon A, Casas R, Tressserra-Rimbau A, et al. (2016) Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: A sub-study of The PREDIMED trial. Br J Clin Pharmacol in press. |
| [200] |
201. Jackson JR, Ryan MJ, Hao Y, Alway SE (2010) Mediation of endogenous antioxidant enzymes and apoptotic signaling by resveratrol following muscle disuse in the gastrocnemius muscles of young and old rats. Am J Physiol Regul Integr Comp Physiol 299: R1572-1581. doi: 10.1152/ajpregu.00489.2010
|
| [201] | 202. Jackson JR, Ryan MJ, Alway SE () Long-term supplementation with resveratrol alleviates oxidative stress but does not attenuate sarcopenia in aged mice. J Gerontol A Biol Sci Med Sci 66: 751-764. |
| [202] |
203. Gordon BS, Delgado-Diaz DC, Carson J, et al. (2014) Resveratrol improves muscle function but not oxidative capacity in young mdx mice. Can J Physiol Pharmacol 92: 243-251. doi: 10.1139/cjpp-2013-0350
|
| [203] |
204. Hori YS, Kuno A, Hosoda R, et al. (2011) Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. J Pharmacol Exp Ther 338: 784- 794. doi: 10.1124/jpet.111.183210
|
| [204] |
205. Tamaki N, Cristina Orihuela-Campos R, Inagaki Y, et al. (2014) Resveratrol improves oxidative stress and prevents the progression of periodontitis via the activation of the Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat periodontitis model. Free Radic Biol Med 75: 222-229. doi: 10.1016/j.freeradbiomed.2014.07.034
|
| [205] |
206. De Oliveira MR, Nabavi SF, Manayi A, et al. (2016) Resveratrol and the mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view. Biochim Biophys Acta 1860: 727-745. doi: 10.1016/j.bbagen.2016.01.017
|
| [206] |
207. Tellone E, Galtieri A, Russo A, et al. (2016) How does resveratrol influence the genesis of some neurodegenerative diseases? Neural Regen Res 11: 86-87. doi: 10.4103/1673-5374.175047
|
| [207] |
209. Shishodia S (2013) Molecular mechanisms of curcumin action: Gene Expression. Biofactors 39: 37–55. doi: 10.1002/biof.1041
|
| [208] | 210. Nikolaidis MG, Kerksick CM, Lamprecht M, et al. (2012) Does vitamin C and E supplementation impair the favorable adaptations of regular exercise? Oxid Med Cell Longev 2012: 707941. |
| [209] |
211. Hawley JA, Burke LM, Phillips SM, et al. (2011) Nutritional modulation of training-induced skeletal muscle adaptations. J Appl Physiol (1985) 110: 834-845. doi: 10.1152/japplphysiol.00949.2010
|
| [210] |
212. Morales-Alamo D, Calbet JA (2014) Free radicals and sprint exercise in humans. Free Radic Res 48: 30-42. doi: 10.3109/10715762.2013.825043
|
| [211] |
213. Strobel NA, Peake JM, Matsumoto A, et al. (2011) Antioxidant supplementation reduces skeletal muscle mitochondrial biogenesis. Med Sci Sports Exerc 43: 1017-1024. doi: 10.1249/MSS.0b013e318203afa3
|
| [212] | 214. Gomez-Cabrera MC, Domenech E, Romagnoli M, et al. (2008) Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am J Clin Nutr 87: 142-149. |
| [213] |
215. Morrison D, Hughes J, Della Gatta PA, et al. (2015) Vitamin C and E supplementation prevents some of the cellular adaptations to endurance-training in humans. Free Radic Biol Med 89: 852-862. doi: 10.1016/j.freeradbiomed.2015.10.412
|
| [214] |
216. Paulsen G, Hamarsland H, Cumming KT, et al. (2014) Vitamin C and E supplementation alters protein signalling after a strength training session, but not muscle growth during 10 weeks of training. J Physiol 592: 5391-5408. doi: 10.1113/jphysiol.2014.279950
|
| [215] | 217. Kataja-Tuomola M, Sundell JR, Mannisto S, et al. (2008) Effect of alpha-tocopherol and beta-carotene supplementation on the incidence of type 2 diabetes. Diabetologia 51: 47-53. |
| [216] |
218. Virtamo J, Edwards BK, Virtanen M, et al. (2000) Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland). Cancer Causes Control 11: 933-939. doi: 10.1023/A:1026546803917
|
| [217] |
219. Zureik M, Galan P, Bertrais S, et al. (2004) Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arterioscler Thromb Vasc Biol 24: 1485-1491. doi: 10.1161/01.ATV.0000136648.62973.c8
|
| [218] | 220. Bjelakovic G, Nikolova D, Simonetti RG, et al. (2004) Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 364: 1219-1228. |
| [219] |
221. Myung SK, Kim Y, Ju W, et al. (2010) Effects of antioxidant supplements on cancer prevention: a meta-analysis of randomized controlled trials. Ann Oncol 21: 166-179. doi: 10.1093/annonc/mdp286
|
| [220] | 222. Bardia A, Tleyjeh IM, Cerhan JR, et al. (2008) Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc 83: 23-34. |
| [221] |
223. Singh U, Jialal I (2006) Oxidative stress and atherosclerosis. Pathophysiology 13: 129-142. doi: 10.1016/j.pathophys.2006.05.002
|
| [222] |
224. Wang FW, Wang Z, Zhang YM, et al. (2013) Protective effect of melatonin on bone marrow mesenchymal stem cells against hydrogen peroxide-induced apoptosis in vitro. J Cell Biochem 114: 2346-2355. doi: 10.1002/jcb.24582
|
| [223] | 225. Sart S, Song L, Li Y (2015) Controlling Redox Status for Stem Cell Survival, Expansion, and Differentiation. Oxid Med Cell Longev 2015: 105135. |
| [224] |
226. Willcox DC, Willcox BJ, Todoriki H, et al. (2006) Caloric restriction and human longevity: what can we learn from the Okinawans? Biogerontology 7: 173-177. doi: 10.1007/s10522-006-9008-z
|
| [225] |
227. Shimizu K, Takeda S, Noji H, et al. (2003) Dietary patterns and further survival in Japanese centenarians. J Nutr Sci Vitaminol (Tokyo) 49: 133-138. doi: 10.3177/jnsv.49.133
|
| [226] | 228. Ji LL, Kang C, Zhang Y (2016) Exercise-induced hormesis and skeletal muscle health. Free Radic Biol Med in press. |
| [227] |
229. Handschin C, Spiegelman BM (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735. doi: 10.1210/er.2006-0037
|
| [228] |
230. Wareski P, Vaarmann A, Choubey V, et al. (2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem 284: 21379-21385. doi: 10.1074/jbc.M109.018911
|
| [229] |
231. Villena JA (2015) New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS J 282: 647-672. doi: 10.1111/febs.13175
|
| 1. | Lu Xu, Chunlai Mu, Qiao Xin, Global boundedness and asymptotic behavior of solutions for a quasilinear chemotaxis model of multiple sclerosis with nonlinear signal secretion, 2023, 28, 1531-3492, 1215, 10.3934/dcdsb.2022118 |
Figures(3)
Vittorio Emanuele Bianchi, Giancarlo Falcioni. Reactive oxygen species, health and longevity[J]. AIMS Molecular Science, 2016, 3(4): 479-504. doi: 10.3934/molsci.2016.4.479
DownLoad:
